Zyprexa News

Mylan receives FDA approval for generic Zyprexa
Mylan Inc. has become the latest drugmaker to receive approval for a generic version of Eli Lilly and Co.'s blockbuster antipsychotic Zyprexa.Mylan, based in Canonsburg, Pa., said Tuesday the Food and ...
Eli Lilly Beyond Zyprexa: Lifts Guidance Despite Patent Loss, Profit Slide
Eli Lilly posted a top and bottom line beat in its first quarter despite the loss of its cash cow drug, Zyprexa. The company raised revenue guidance, while maintaining its revenue forecast.
Zyprexa sales hurt Lilly 1Q profits
Eli Lilly and Co. said Wednesday that its first quarter profit fell 4 percent, as generic competition cut into sales of its all-time best-seller, the antipsychotic drug Zyprexa. Read more at www.WISHTV.com
Drop in Zyprexa sales dampens Lilly's sales, profits
Nothing can fill the yawning revenue gap caused by Zyprexa's plunging sales. Eli Lilly and Co.'s all-time best-selling drug saw 56 percent, or $719 million, of sales vanish in the first quarter, as cheaper generics rapidly grabbed market share from the drug after its U.S. patent expired last fall.
Lilly 1Q profit slides 4 pct, Zyprexa sales fall
Eli Lilly and Co. said Wednesday that its first quarter profit fell 4 percent, as generic competition cut into sales of its all-time best-seller, the antipsychotic drug Zyprexa.
Mylan Launches Generic Version of Zyprexa® Tablets
PITTSBURGH, April 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL - News) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration ...
Lilly quarterly sales, profit beats forecasts
(Reuters) - Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products. The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because ...
Lilly Reports Solid Start to the Year With First-Quarter 2012 Results, Raises EPS Guidance
INDIANAPOLIS, April 25, 2012 /PRNewswire/ --Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in other products ...
Dr. Reddy’s Announces the Launch of Olanzapine Tablets
Dr. Reddy’s Laboratories announced today that it has launched Olanzapine Tablets , a bioequivalent generic version of ZYPREXA® Tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration of Dr.
Eli Lilly Lifts Forecast Even As Zyprexa Patent Loss Hurts
Drugmaker Eli Lilly and Co. on Wednesday reported a slight decline in first-quarter profit, as sales of its schizophrenia drug Zyprexa halved due to patent expirations. Adjusted earnings and revenues came in well above Wall Street estimates aided by 'significant' growth in other products and key regions, helping the company lift its full-year earnings guidance. In the first quarter, net income ...